Cargando…
Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
Few studies have assessed the benefits of androgen deprivation therapy (ADT) in men with metastatic prostate cancer (PC; mPC) at an old age or with major cardiovascular conditions. A retrospective cohort consisted of 3835 men with newly diagnosed mPC from the Taiwan Cancer Registry of 2008–2014. Amo...
Autores principales: | Wu, Szu-Yuan, Fang, Su-Chen, Hwang, Olivia Rachel, Shih, Hung-Jen, Shao, Yu-Hsuan Joni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016583/ https://www.ncbi.nlm.nih.gov/pubmed/31940958 http://dx.doi.org/10.3390/cancers12010189 |
Ejemplares similares
-
Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021) -
Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021) -
Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014) -
AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2015) -
AB187. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2016)